Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Livopara
- Development stage
- Unknown
- Lead developer
- Kley Hertz
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Livopara** is an oral fixed-dose anti-cold tablet marketed by Aarise Pharmaceuticals. It combines levocetirizine, an H1 antihistamine that reduces allergy-related sneezing, rhinorrhea, and itching; paracetamol, an analgesic and antipyretic; and phenylephrine, an alpha-1 adrenergic agonist used as a nasal decongestant. The product is marketed for symptomatic relief of common-cold and allergy-associated symptoms including nasal congestion. ([drugtodayonline.com](https://www.drugtodayonline.com/drug-directory/brand_info/livopara85))
- Brand names
- Livopara
- Other names
- levocetirizine + paracetamol + phenylephrine
02
Targets
ADRA1A (α1A)HRH1 (Histamine H1 Receptor)COX
Beyond the preview
Go deeper on Livopara.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Livopara.